CORE--DRUG EVALUATION

药物评价核心的总体目标是为以下方面提供支持 调查人员要求的常规程序、化验和分析 计划项目。一般来说，将使用现有的方法。新的 方法，或已建立的方法的修改，将使用 根据需要提供项目和核心。 Core使用的方法包括但不限于 以下是： (I)使用计算机估计，测量药物的亲脂性， 高效液相保留时间与油：缓冲液分配法； (2)测定细胞、组织和生物中的药物含量 使用吸光度、荧光法和提取/溶解方法的流体。 这些方法将在培养细胞、动物模型和 临床试验中的患者； (3)测定光敏剂浓度，使用 非侵入性原位反射光谱和荧光法。这些 测量将在动物模型和临床患者中进行。 试验； (4)测量肿瘤对光动力疗法的反应，包括维持 电子卡尺肿瘤测量与维护的电子化 计算机化数据存储系统； (V)使用荧光素测量血管对光动力疗法的反应 排除法和特殊构建的非侵入性原位检测 荧光计； (Vi)利用该井测量对光动力疗法的正常组织毒性 建立小鼠足部反应模型； (Vii)在体外和体外测量细胞对光动力疗法的反应 体内/体外(切除实验)模型； (Viii)检测细胞、组织中的光敏剂和代谢物 和液体使用分析型高效液相色谱仪。 (Ix)用高吸光度测定光敏剂的白蛋白结合量 性能置换层析； (X)测定光敏剂的组织和细胞部位 共聚焦荧光显微镜定位； (Xi)组织学标本的制备、组织学方法 发展。 药物评价核心的活动对以下方面至关重要 最大限度地从综合项目中获得有用信息 和本计划项目中的核心。核心人员将执行、指导或 监督这些例行程序，从而提高一致性，如 以及规模经济；这种整合也将提高质量 控件，并将使在项目之间交换数据变得更加可行。

The overall aim of the Drug Evaluation Core is to provide support for routine procedures, assays and analyses required by the investigators of the Program Project. Generally, existing methodology will be used. New methods, or modifications of established methods, will be developed with the Projects and Cores as needed. Methods to be used by the Core include, but are not limited to, the following: (i) measurement of drug lipophilicity, using computer estimates, HPLC retention times and oil:buffer partitioning methods; (ii) determination of drug levels in cells, tissues and biological fluids using absorbance, fluorescence and extraction/dissolution methods. These methods will be performed for cultured cells, animal models, and patients in clinical trials; (iii) determination of photosensitizer concentrations using noninvasive in situ reflectance spectroscopy and fluorimetry. These measurements will be performed in animal models and patients in clinical trials; (iv) measurement of tumor response to PDT, including maintenance of electronic maintenance of electronic-caliper tumor measurement and computerized data storage systems; (v) measurement of vascular response to PDT using a fluorescein exclusion assay and specially constructed, non-invasive in situ fluorometer; (vi) measurement of normal tissue toxicity to PDT using the well established murine foot response model; (vii) measurement of cellular responses to PDT using in vitro and in vivo/ex vivo (excision assay) models; (viii)detection of photosensitizers and metabolites in cells, tissues and fluids using analytical HPLC. (ix) measurement of albumin binding of photosensitizers using high- performance displacement chromatography; (x) determine tissue and cellular sites of photosensitizer localization using confocal fluorescence microscopy; (xi) preparation of specimens for histology, histology method development. The activities of the Drug Evaluation Core will be essential for maximizing the yield of useful information from the integrated Projects and Cores in this Program Project. Core personnel will perform, direct or supervise these routine procedures, resulting in increased consistency as well as economy of scale; this consolidation will also improve quality control and will make it more feasible to exchange data between Projects.